RANBAXY - Stretched Balance Sheet, a Weak Product Pipeline, and Uncertainty around Monetizing Exclusivities
Q2 CY-13 Result in Line: Sales grew by 8% QoQ primarily on account of higher Absorica (Isotretinoin) sales in US. US sales grew by 29% sequentially as company now has 14% share in Isotretinion (~$400m market). Excluding US, revenue across the geographies remained muted and grew by 1% sequentially and 2% yoy.
EBITDA margin at 9.8%, has improved by 220 bps on sequential basis mainly due to high margin sales of Isotretinoin and INR depreciation. Forex loss of Rs.5403m and impairment of goodwill of Rs.1192m in France resulted in loss of Rs5242m at net level.
EBITDA margin at 9.8%, has improved by 220 bps on sequential basis mainly due to high margin sales of Isotretinoin and INR depreciation. Forex loss of Rs.5403m and impairment of goodwill of Rs.1192m in France resulted in loss of Rs5242m at net level.
More Publications
SUN PHARMA: Strong Quarter and Brighter Outlook
US$ 140.00
May 2012
7 pages
DISHMAN, Worry on Cash Flow Continues
US$ 140.00
January 2013
6 pages
IPCA- Ready to Fire from All Directions
US$ 140.00
May 2012
7 pages
TOP TEN ANDA / PARA-IV / API OPPORTUNITIES TO BE TARGETED BY GENERIC OR ACTIVE PHARMACEUTICAL INGREDIENT COMPANIES
US$ 5,000.00
March 2012
60 pages
CADILA HEALTHCARE LTD - In a Consolidation Phase
US$ 140.00
July 2011
6 pages
